TwinStrand Biosciences Analysis: $67M Raised
What is TwinStrand Biosciences?
Duplex Sequencing technology for ultra-sensitive analysis
Location
Seattle, United States
Employees
51-200
Founded
2015
Product Features & Capabilities
- AML Assay
- Mutagenesis Assay
- Nitrosamine Testing
- Mutagenesis Testing
Use Cases
Measure minimal residual disease in acute myeloid leukemia; Identify mutations with high resolution; Monitor cellular immunotherapy effectiveness; Assess mutagenicity in regulatory studies; Detect low-frequency variants in genomic research
Other Considerations
Initiated regulatory approval process for Duplex Sequencing assays; Collaborated with Health Canada for inter-laboratory validation studies; Published research demonstrating technology's effectiveness in mutagenicity assessments
See something that needs updating? Suggest edits to this profile.